Multivariate analyses
| Cohorts and variables . | PFS, HR (95% CI) . | OS, HR (95% CI) . |
|---|---|---|
| Entire cohort | n = 79 | n = 109 |
| Age (>60 y vs ≤60 y) | Not included | 1.49 (0.93-2.40), P = .099 |
| Performance status (2-4 vs 0-1) | Not included | 1.17 (0.67-2.06), P = .587 |
| LDH (elevated vs normal) | 1.61 (0.96-2.70), P = .071 | Not included |
| Treatment (HDMTX vs others) | 0.69 (0.43-1.11), P = .125 | 0.30 (0.19-0.46), P < .001 |
| BCL6 FISH (positive vs negative) | 2.06 (1.22-3.49), P = .007 | 1.55 (0.98-2.46), P = .064 |
| HDMTX only | n = 48 | n = 45 |
| Sex (male vs female) | Not included | 2.59 (1.16-5.81), P = .021 |
| LDH (elevated vs normal) | 1.76 (0.89-3.48), P = .104 | Not included |
| LMO2 IHC (positive vs negative) | Not included | 1.33 (0.61-2.92), P = .479 |
| BCL6 FISH (positive vs negative) | 2.62 (1.33-5.17), P = .006 | 1.12 (0.46-2.71), P = .806 |
| Cohorts and variables . | PFS, HR (95% CI) . | OS, HR (95% CI) . |
|---|---|---|
| Entire cohort | n = 79 | n = 109 |
| Age (>60 y vs ≤60 y) | Not included | 1.49 (0.93-2.40), P = .099 |
| Performance status (2-4 vs 0-1) | Not included | 1.17 (0.67-2.06), P = .587 |
| LDH (elevated vs normal) | 1.61 (0.96-2.70), P = .071 | Not included |
| Treatment (HDMTX vs others) | 0.69 (0.43-1.11), P = .125 | 0.30 (0.19-0.46), P < .001 |
| BCL6 FISH (positive vs negative) | 2.06 (1.22-3.49), P = .007 | 1.55 (0.98-2.46), P = .064 |
| HDMTX only | n = 48 | n = 45 |
| Sex (male vs female) | Not included | 2.59 (1.16-5.81), P = .021 |
| LDH (elevated vs normal) | 1.76 (0.89-3.48), P = .104 | Not included |
| LMO2 IHC (positive vs negative) | Not included | 1.33 (0.61-2.92), P = .479 |
| BCL6 FISH (positive vs negative) | 2.62 (1.33-5.17), P = .006 | 1.12 (0.46-2.71), P = .806 |
LDH, lactate dehydrogenase.